Earlier this year, a cancer drug became the latest addition to a growing list of antiviral drugs repurposed to treat COVID-19. In April 2021, clinical trials in Brazil reported that proxalutamide had reduced mortality rates in hospitalized patients by 77%. Suzhou Kintor Pharmaceuticals, the pharma company which originally developed proxalutamide to treat prostate cancer, has since launched its own clinical trial in May to examine proxalutamide’s potential when treating the viral infection.
Some believe the results are just too good to be true. The Brazilian study is under investigation by the country’s National Research Ethics Commission with respect to irregularities in reporting trial deaths.
There is widespread concern that the effectiveness of proxalutamide as an anti-COVID-19 treatment, what President Jair Bolsonaro calls a ‘potential miracle cure’, is not supported by conclusi...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).